Clinical long-time course, novel mutations and genotype-phenotype correlation in a cohort of 27 families with POMT1 -related disorders | Orphanet Journal of Rare Diseases | Full Text

Clinical long-time course, novel mutations and genotype-phenotype correlation in a cohort of 27 families with POMT1 -related disorders | Orphanet Journal of Rare Diseases | Full Text



Orphanet Journal of Rare Diseases

Clinical long-time course, novel mutations and genotype-phenotype correlation in a cohort of 27 families with POMT1-related disorders

• Tobias Geis, 
• Tanja Rödl, 
• Haluk Topaloğlu, 
• Burcu Balci-Hayta, 
• Sophie Hinreiner, 
• Wolfgang Müller-Felber, 
• Benedikt Schoser, 
• Yasmin Mehraein, 
• Angela Hübner, 
• Birgit Zirn, 
• Markus Hoopmann, 
• Heiko Reutter, 
• David Mowat, 
• Gerhard Schuierer, 
• Ulrike Schara, 
• Ute Hehr & 
• Heike Kölbel 

Orphanet Journal of Rare Diseasesvolume 14, Article number: 179 (2019) | Download Citation

Abstract

Background

The protein O-mannosyltransferase 1, encoded by the POMT1 gene, is a key enzyme in the glycosylation of α-dystroglycan. POMT1–related disorders belong to the group of dystroglycanopathies characterized by a proximally pronounced muscular dystrophy with structural or functional involvement of the brain and/or the eyes. The phenotypic spectrum ranges from the severe Walker-Warburg syndrome (WWS) to milder forms of limb girdle muscular dystrophy (LGMD). The phenotypic severity of POMT1-related dystroglycanopathies depends on the residual enzyme activity. A genotype-phenotype correlation can be assumed.

Results

The clinical, neuroradiological, and genetic findings of 35 patients with biallelic POMT1 mutations (15 WWS, 1 MEB (muscle-eye-brain disease), 19 LGMD) from 27 independent families are reported. The representative clinical course of an infant with WWS and the long-term course of a 32 years old patient with LGMD are described in more detail. Specific features of 15 patients with the homozygous founder mutation p.Ala200Pro are defined as a distinct and mildly affected LGMD subgroup. Ten previously reported and 8 novel POMT1 mutations were identified. Type and location of each of the POMT1 mutations are evaluated in detail and a list of all POMT1 mutations reported by now is provided. Patients with two mutations leading to premature protein termination had a WWS phenotype, while the presence of at least one missense mutation was associated with milder phenotypes. In the patient with MEB-like phenotype two missense mutations were observed within the catalytic active domain of the enzyme.

Conclusions

Our large cohort confirms the importance of type and location of each POMT1mutation for the individual clinical manifestation and thereby expands the knowledge on the genotype-phenotype correlation in POMT1-related dystroglycanopathies. This genotype-phenotype correlation is further supported by the observation of an intrafamiliar analogous clinical manifestation observed in all affected 13 siblings from 5 independent families. Our data confirm the progressive nature of the disease also in milder LGMD phenotypes, ultimately resulting in loss of ambulation at a variable age. Our data define two major clinical POMT1phenotypes, which should prompt genetic testing including the POMT1 gene: patients with a severe WWS manifestation predominantly present with profound neonatal muscular hypotonia and a severe and progressive hydrocephalus with involvement of brainstem and/or cerebellum. The presence of an occipital encephalocele in a WWS patient might point to POMT1 as causative gene within the different genes associated with WWS. The milder LGMD phenotypes constantly show markedly elevated creatine kinase values in combination with microcephaly and cognitive impairment.